Michael S Leapman1, Hao G Nguyen2, Janet E Cowan2, Lingru Xue2, Bradley Stohr3, Jeffry Simko3, Matthew R Cooperberg4, Peter R Carroll2. 1. Department of Urology, Yale University School of Medicine, New Haven, CT, USA. Electronic address: michael.leapman@yale.edu. 2. Department of Urology, University of California San Francisco, San Francisco, CA, USA. 3. Department of Pathology, University of California San Francisco, San Francisco, CA, USA. 4. Department of Urology, University of California San Francisco, San Francisco, CA, USA; Department of Epidemiology and Biostatistics, University of California San Francisco, San Francisco, CA, USA.
Abstract
BACKGROUND: Despite the availability of numerous genomic predictors of prostate cancer (PCa) outcome, few comparative studies have been performed. OBJECTIVE: To compare the prognostic utility of previously validated immunohistochemical (IHC) markers with an expression-based cell-cycle progression (CCP) score. DESIGN, SETTING, AND PARTICIPANTS: We identified 424 men with localized PCa treated with radical prostatectomy (RP). IHC analysis was performed using a tissue microarray to examine the expression status of PTEN, Ki-67, and ERG compared with previously calculated CCP scores derived from 31 genes normalized to 15 housekeeper genes. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Associations of IHC status and CCP scores, adjusted for clinical and pathologic characteristics were performed using Cox regression and competing risks regression to examine risk of biochemical recurrence (BCR), and metastasis or PCa-specific mortality (PCSM). We compared models using concordance index (c-index) testing. INTERVENTION: RP. RESULTS AND LIMITATIONS: Median age at treatment was 59 yr, and patients were followed for a median of 114 mo after RP. By 10 yr after RP, 27% experienced BCR and 4% developed metastasis or PCSM. In a multivariable model adjusted for Cancer of the Prostate Risk Assessment score (CAPRA-S), CCP was associated with risks of recurrence (hazard ratio [HR] 1.51, 95% confidence interval [CI] 1.08-2.11) and metastasis/PCSM (HR 2.15, 95% CI 1.36-3.39). PTEN loss was not associated with recurrence but was associated with metastasis/PCSM (HR 5.26, 95% CI 2.57-10.7), adjusted for CAPRA-S. The c-index for models consisting of PTEN status and CAPRA-S was similar (0.80) for risk of metastasis/PCSM when compared with CCP and CAPRA-S (0.81). Integration of Ki-67 and ERG status did not improve the c-index relative to CAPRA-S and PTEN alone. CONCLUSIONS: PTEN status offered comparable discrimination of the risk of metastasis or death from PCa relative to a commercial RNA amplification-based CCP assay. Efforts are warranted to reduce the cost of PCa prognostic tools in order to expand access. PATIENT SUMMARY: We compared a commercial genomic signature and the expression status of single genes to predict outcomes in men with prostate cancer who were treated with surgical removal. When accounting for clinical information about the patient's cancer, the status of the PTEN gene alone matched a multigene panel to predict which patient's cancer would metastasize or lead to death from the disease. Published by Elsevier B.V.
BACKGROUND: Despite the availability of numerous genomic predictors of prostate cancer (PCa) outcome, few comparative studies have been performed. OBJECTIVE: To compare the prognostic utility of previously validated immunohistochemical (IHC) markers with an expression-based cell-cycle progression (CCP) score. DESIGN, SETTING, AND PARTICIPANTS: We identified 424 men with localized PCa treated with radical prostatectomy (RP). IHC analysis was performed using a tissue microarray to examine the expression status of PTEN, Ki-67, and ERG compared with previously calculated CCP scores derived from 31 genes normalized to 15 housekeeper genes. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Associations of IHC status and CCP scores, adjusted for clinical and pathologic characteristics were performed using Cox regression and competing risks regression to examine risk of biochemical recurrence (BCR), and metastasis or PCa-specific mortality (PCSM). We compared models using concordance index (c-index) testing. INTERVENTION: RP. RESULTS AND LIMITATIONS: Median age at treatment was 59 yr, and patients were followed for a median of 114 mo after RP. By 10 yr after RP, 27% experienced BCR and 4% developed metastasis or PCSM. In a multivariable model adjusted for Cancer of the Prostate Risk Assessment score (CAPRA-S), CCP was associated with risks of recurrence (hazard ratio [HR] 1.51, 95% confidence interval [CI] 1.08-2.11) and metastasis/PCSM (HR 2.15, 95% CI 1.36-3.39). PTEN loss was not associated with recurrence but was associated with metastasis/PCSM (HR 5.26, 95% CI 2.57-10.7), adjusted for CAPRA-S. The c-index for models consisting of PTEN status and CAPRA-S was similar (0.80) for risk of metastasis/PCSM when compared with CCP and CAPRA-S (0.81). Integration of Ki-67 and ERG status did not improve the c-index relative to CAPRA-S and PTEN alone. CONCLUSIONS:PTEN status offered comparable discrimination of the risk of metastasis or death from PCa relative to a commercial RNA amplification-based CCP assay. Efforts are warranted to reduce the cost of PCa prognostic tools in order to expand access. PATIENT SUMMARY: We compared a commercial genomic signature and the expression status of single genes to predict outcomes in men with prostate cancer who were treated with surgical removal. When accounting for clinical information about the patient's cancer, the status of the PTEN gene alone matched a multigene panel to predict which patient's cancer would metastasize or lead to death from the disease. Published by Elsevier B.V.
Entities:
Keywords:
Cell-cycle progression; PTEN; Prostate cancer; Prostate cancer mortality; Recurrence
Authors: Danijel Sikic; Markus Eckstein; Ralph M Wirtz; Jonas Jarczyk; Thomas S Worst; Stefan Porubsky; Bastian Keck; Frank Kunath; Veronika Weyerer; Johannes Breyer; Wolfgang Otto; Sebastien Rinaldetti; Christian Bolenz; Arndt Hartmann; Bernd Wullich; Philipp Erben Journal: J Clin Med Date: 2020-04-02 Impact factor: 4.241
Authors: Oliver Hommerding; Yves Allory; Pedram Argani; Tarek A Bismar; Lukas Bubendorf; Sofía Canete-Portillo; Alcides Chaux; Ying-Bei Chen; Liang Cheng; Antonio L Cubilla; Lars Egevad; Anthony J Gill; David J Grignon; Arndt Hartmann; Ondrej Hes; Muhammad T Idrees; Chia-Sui Kao; Margaret A Knowles; Leendert H J Looijenga; Tamara L Lotan; Colin C Pritchard; Mark A Rubin; Scott A Tomlins; Theodorus H Van der Kwast; Elsa F Velazquez; Joshua I Warrick; Sean R Williamson; Glen Kristiansen Journal: Pathologe Date: 2021-01-04 Impact factor: 1.011
Authors: Konrad H Stopsack; Ying Huang; Svitlana Tyekucheva; Travis A Gerke; Clyde Bango; Habiba Elfandy; Michaela Bowden; Kathryn L Penney; Thomas M Roberts; Giovanni Parmigiani; Philip W Kantoff; Lorelei A Mucci; Massimo Loda Journal: Clin Cancer Res Date: 2020-09-10 Impact factor: 12.531
Authors: Eddie Luidy Imada; Diego Fernando Sanchez; Wikum Dinalankara; Thiago Vidotto; Ericka M Ebot; Svitlana Tyekucheva; Gloria Regina Franco; Lorelei Ann Mucci; Massimo Loda; Edward Matthew Schaeffer; Tamara Lotan; Luigi Marchionni Journal: BMC Cancer Date: 2021-07-26 Impact factor: 4.430